Abstract:Delayed cerebral ischemia as a result of cerebral vasospasm is the most common cause of death and disability after aneurysmal subarachnoid hemorrhage (SAH). It leads to death or permanent neurologic deficits in over 17-40% of SAH patients. The initial and main symptom of cerebral vasospasm is diffuse headache and may be accompanied with a slight increase in discomfort from neck stiffness and fever. The clinical diagnosis of cerebral vasospasm is made when the patient experiences an altered level of consciousness or a new focal neurologic deficit. There has been a great progress in identifying the patients at risk, putative mechanisms, and possible treatment options for cerebral vasospasm. However, the problem is by no means solved, mainly due to a limited understanding of the pathologic mechanisms of this complex disease. The iatrogenic factors that can increase the risk of cerebral vasospasm include prolongation of the subarachnoid clot by antifibrinolytic drugs, hypotension, inappropriate treatment of hyponatremia, hypovolemia, hyperthermia and increased intracranial pressure. Nimodipine has been shown to improve neurologic outcome and decrease the incidence of cerebral vasospasm. Triple H therapy is a treatment designed to augment cerebral blood flow for patient with cerebral vasospasm. Hypervolemic hypertension is induced with intravenous volume expansion with crystalloid or colloid to increase cardiac output and raise blood pressure. However, small randomized trials showed no clear benefit. Recently, balloon and chemical angioplasty with superselective intra-arterial injection of vasodilators has emerged as the primary intervention for treating medically refractory ischemia from cerebral vasospasm and in many centers is being used as a first-line treatment or even prophylactically. In addition, promising new treatments for cerebral vasospasm or its ischemic complications include magnesium sulfate, fasudil hydrochloride, tirilazad mesylate, erythropoietin, and induced hypothermia; however, all still need further clinical trials. Newly recognized mediators of cerebral vasospasm after SAH include endothelium-derived mediators, vascular smooth-muscle-derived mediators, proinflammatory mediators involved in blood-brain barrier disruption, cytokines and adhesion molecules, stress-induced gene activation, and platelet-derived growth factors. Moreover, observations in the laboratory have, in many circumstances, matched those of reported small series. Larger, prospective, randomized trials are needed to verify several hypotheses of molecular pathophysiology and clinical treatment regimens.

Triple-H Therapy for Cerebral Vasospasm Following Spontaneous Subarachnoid Hemorrhage

Treatment of cerebral vasospasm after subarachnoid hemorrhage--a review

Current Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage

Eicosapentaenoic acid prevents cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A meta-analysis

The Mechanisms of Cerebral Vasospasm Caused by Subarachnoid Hemorrhage and Its Clinical Treatment Progress

Stem Cell Therapy: A Promising Therapeutic Method for Intracerebral Hemorrhage.

Current State and Clinical Progress on Therapy of Sequent Cerebral Vasospasm in Subarachnoid Hemorrhage

Hypothermia Treatment on Cerebral Vasospasm Induced by Aneurysm Subarachnoid Hemorrhage

Cerebrospinal Fluid Replacement Therapy for the Clinical Effects of Subarachnoid Hemorrhage

[Endovascular Treatment of Delayed Cerebral Vasospasms]

Current Controversies in the Prediction, Diagnosis, and Management of Cerebral Vasospasm: Where Do We Stand?

Intrathecal treatment of cerebral vasospasm

Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought

Cerebral Vasospasm: Practical Review of Diagnosis and Management

Neurovascular disease, diagnosis, and therapy: Subarachnoid hemorrhage and cerebral vasospasm

Progression of Mechanism Research in Cerebral Vasospasm after Subarachnoid Hemorrhage

Intraarterial Infusion of Verapamil for Treatment of Vasospasm after Aneurismal Subarachnoid Hemorrhage

Prevention and Treatment of Venous Thromboembolism in Patients with Intracranial Hemorrhage

Efficacy of endovascular therapy for cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

Endovascular therapy for vasospasm secondary to subarachnoid hemorrhage: A meta-analysis and systematic review.

Clinical study of rho-kinase inhibitor therapy on cerebral vasospasm following traumatic subarachnoid hemorrhage